Generics 10

Biosimilars

Medical devices

Nutraceuticals

Filters

Levosimendan manufacturers

10 products found

Filters

10 products found

levosimendan

Concentrate for solution for infusion 2.5mg/ ml

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Russia, Kazakhstan, Iran

Manufacturer #1586

A pharmaceutical manufacturer based in the EU that has been selling its products in Europe, the Middle East, CIS, LATAM, and Asia for 10+ years. The company's production lines are GMP-compliant. Main dosage forms include solid, liquid, and injection. The company prepares dossier in EU CTD format.

Manufacturer usually replies in 7 days

levosimendan

Concentrate for solution for infusion 2.5 mg/ml

Dossier type
EU CTD
Country of origin
India
Dossier status
Under Development
Clinical data
Not required
GMP approvals
EU GMP
Unavailable markets
Sweden, Norway, Denmark, Finland, Germany, United Kingdom

Manufacturer #12980

It is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain to be able to deliver cost-efficient medicines of the highest quality to pharmacies and hospitals, primarily in the Nordic region. The company conducts extensive development activities in collaboration with partners in Asia, Europe, and India. The strategy is to develop generic medicines in areas where the competition is limited, so-called niche generics. The entire business is based on delivering the cheapest medicines to pharmacies and hospitals, in this way daily lowering the cost of high-quality drugs for patients and society.

Manufacturer usually replies in 18 days

levosimendan

Vials, injection 2.5mg/ml

Dossier type
EU CTD
Country of origin
India
Dossier status
Ready
GMP approvals
EU GMP

Manufacturer #15910

Manufacturer usually replies in 12 days

Want to view all 10 products? Create your free account today!

LEVOSIMENDAN

Levosimendan belongs ta category of medicines called calcium sensitisers. It is used to manage acute decompensated congestive heart failure. It works by increasing the sensitivity of the heart to calcium thus increasing cardiac contractility without arising in intracellular action. It is one of a new class of heterogeneous agents, the calcium sensitisers. Its dual mechanism of action enhances cardiac contractility and vasodilatation without affecting intracellular free calcium, thereby reducing the proarrhythmic potential. It can be administered intravenously (IV) which makes it a therapeutic option for acute decompensated Congestive Heart failure and it is tolerated well in patients with acute heart failure. It has favorable effects on neuro-hormone levels in heart failure patients. These properties make it a good medication to treat heart failure (acute and chronic), sepsis, post-resuscitation myocardial dysfunction and peri-operative optimization of cardiac patients with cardiomyopathy.
Levosimendan is sold under the brand names SIMDAX , Dopamine, Digoxin amongst others.
The Orion Corporation originally developed Levosimendan. They applied for a new drug patent in 1998 in the U.S, which was later withdrawn due to FDA request to conduct further trials. Then in 2000, Sweden became the first country to allow the sale of Levosimendan. More than 60 countries worldwide have approved the drug; however, it is yet to receive its FDA approval in North America, where it is currently in Phase III of development.

Forms and Dosage:

Levosimendan is available in a vial containing 12.5mg in 5ml. Levosimendan infusion starting dose is 0.1 mg per kilo per minute and titrated to 0.2 mg/kg/min as long as systolic blood pressure remains stable after the first 2–3 hours. In the treatment of acute heart failure, the recommended interval is 24 hours. To prevent the risk of hypotension in patients who have systolic blood pressure Initial bolus of Levosimendan is usually not administered.

The price of Levosimendan

In India, consumers have to pay $8 for 12.5 mg for injection for 1 Box of Lyophilized vial.

How does it work?

Levosimendan improves myocytes’ calcium sensitivity as it binds to troponin C in a calcium-dependent manner. The resulting outcome is an increase in contractility without raising calcium levels. Its actions relax vascular smooth muscles by opening adenosine triphosphate sensitive potassium channels.

Finding Levosimendan Manufacturers and Suppliers:

The process of finding trusted Levosimendan manufacturers and Levosimendan suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use online platform to grow your business opportunities. The robust search engine makes it convenient to search for manufacturers and suppliers of Levosimendan. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier easily.